Search
Neoplasms Clinical Trials
A listing of 68 Neoplasms clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 68
There are currently 68 active clinical trials seeking participants for Neoplasms research studies. The states with the highest number of trials for Neoplasms participants are California, Texas, Florida and New York.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
High blood pressure (Hypertension) Trials
Recruiting
High blood pressure (Hypertension) trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
High blood pressure (Hypertension)
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
Recruiting
This is a Phase I/II study to determine the safety and immune response of the H1299 cell lysate vaccine mixed with Montanide(R) ISA-51 VG adjuvant, to be administered on the study in combination with Entinostat and Nivolumab in eligible participants with locally advanced esophageal cancers (EsC) following either neoadjuvant chemoradiation therapy (nCRT) or nCRT and surgery. Phase I of the protocol aims to determine the safe dose of the H1299 lung cancer cell lysate vaccine mixed with Montanide(R... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
06/20/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms, Esophageal Neoplasms, Esophagus Neoplasm, Esophagus Cancer, Neoplasms, Esophageal, Esophageal Cancer (EsC)
Clinical and Genetic Studies of Li-Fraumeni Syndrome
Recruiting
Background:
- Li-Fraumeni syndrome (LFS) is a genetic condition that increases the risk for some types of cancer. LFS may lead to cancer of the bone or connective tissue, breast, and brain. It may also increase the risk for certain types of leukemia and other cancers. The only known cause of LFS is a change (called a mutation ) in a gene known as TP53. However, not all people with LFS have a TP53 mutation. Researchers want to study other possible genetic causes of LFS, and factors that may incr... Read More
Gender:
All
Ages:
All
Trial Updated:
06/19/2024
Locations: National Cancer Institute - Shady Grove, Bethesda, Maryland +1 locations
Conditions: Li-Fraumeni Syndrome, Neoplasms, Tp53 Mutations
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Goodyear, Arizona +95 locations
Conditions: Neoplasms
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Recruiting
The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D[s]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: City of Hope, Duarte, California +12 locations
Conditions: Myeloproliferative Disorders, Essential Thrombocythemia, Neoplasms, Myelofibrosis
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
Recruiting
Background:
Blood, tissue, and tumor cells contain genes. Genes are made up of DNA. DNA is the instruction book for each cell. In some people with cancer, the genes that might have slowed the growth of their tumor were turned off. Researchers want to see if a new drug can turn the genes back on and slow the tumor growth. The drug is called Aza-TdC.
Objective:
To test the safety of Aza-TdC, and to find out the dose of this drug that can be safely given to humans.
Eligibility:
People ages 18... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
06/13/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms, Solid Tumors
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Recruiting
Background:
People with rare cancers often have limited treatment options. The biology of rare cancers is not well understood. Researchers want to find better treatments for these cancers. They want to test 2 drugs that, taken separately, have helped people with non-rare cancers. They want to see if these drugs together can make rare cancers shrink or stop growing.
Objective:
To learn if nilotinib and paclitaxel will benefit people with rare cancers.
Eligibility:
People age 18 and older who... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
06/13/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms
Endometrial Cell Collection With the PadKit
Recruiting
All patients will be provided with a Preprogen Pad to be worn for 4-6 hours to collect cells shed by the endometrium. After the kit is returned to the Preprogen laboratory, a brief survey will be completed. Analysis will be conducted to determine if the PadKit™ can collect a sample of endometrial cells sufficient to differentiate between normal and atypical hyperplasia/malignant cells in blinded samples provided to the laboratory for analysis.
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: Jersey Shore University Medical Center, Neptune, New Jersey +1 locations
Conditions: Neoplasms
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
Recruiting
Background:
- Researchers want to develop better ways to treat cancer. In this study, they will give people with cancer two drugs. These drugs have been used on their own to treat some blood cell cancers.
Objectives:
- To test the safety and efficacy of the drug combination of bortezomib and clofarabine.
Eligibility:
- Adults age 18 and over with advanced cancer that has progressed after receiving standard treatment or that has no effective therapy.
Design:
Participants will be screened w... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
06/12/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms, Myelodysplastic Syndromes, Lymphomas
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Recruiting
The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.
Gender:
All
Ages:
All
Trial Updated:
06/11/2024
Locations: Chao Family Comprehensive Cancer Center; UC Irvine Medical Center, Orange, California +34 locations
Conditions: Neoplasms
Sample Collection and Tracking for the Developmental Therapeutics Clinic
Recruiting
Background:
People who join a study in the Developmental Therapeutics Clinic (DTC) have tests. These include blood draws and biopsies. Researchers collect data from these samples. Some people take part in more than one study at the DTC. At this time, data are connected only with one single study. Researchers want to access people s medical records. This will allow them to link the research data from all their studies they have or will take part in. Researchers also want to collect medical data... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/08/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms, Lymphoma
Collection of Tissue Samples for Cancer Research
Recruiting
Background:
-Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens.
Objectives:
To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment.
To obtain samples for re... Read More
Gender:
All
Ages:
2 months and above
Trial Updated:
06/06/2024
Locations: UC Davis, Sacramento, California +16 locations
Conditions: Neoplasms, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
Recruiting
The purpose of this study is to evaluate the effect of moderate or severe liver impairment on the drug levels of oral azacitidine and the safety and tolerability of oral azacitidine in participants with myeloid malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: University of Iowa, Iowa City, Iowa +21 locations
Conditions: Hepatic Insufficiency, Neoplasms
1 - 12 of 68